Assignee
NANJING SANHOME PHARMACEUTICAL CO LTD
CN·9 granted patents·9 pending applications·7 citations·filing 2013–2021
Top patents by PatentIndex Score
18 records- 0182US11186587B2Compound as ACC inhibitor and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 30, 2021·3 cites·8 claims
- 0276US10093656B2Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitorNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2017·Granted Oct 9, 2018·2 cites·14 claims
- 0371US9255107B2Heteroaryl alkyne compound and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2013·Granted Feb 9, 2016·1 cites·18 claims
- 0462US10077258B2Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2016·Granted Sep 18, 2018·1 cites·17 claims
- 0556US2024262915A1Anti-tigit antibody and double antibody and their applicationNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0652US2021395235A1COMPOUND AS TGF-beta R1 INHIBITOR AND APPLICATION THEREOFNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 0751US2022332829A1Anti-b7-h3 antibody and application thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 0850US12473280B2Substituted tricyclic compound as PRMT5 inhibitor and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 18, 2025·0 cites·11 claims
- 0949US2023090014A1Anti-cd47/anti-pd-l1 antibody and applications thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1047US11987627B2Anti-CD47 antibody and application thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2019·Granted May 21, 2024·0 cites·8 claims
- 1147US2023002355A1Compound as shp2 inhibitor and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 1246US2013202698A1L-ornidazole formulations and their applications in treatment of parasitic infectionsNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 1344US2022002288A1Monobactam compounds and use thereforNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 1441US9512108B29,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2014·Granted Dec 6, 2016·0 cites·19 claims
- 1541US2015152088A1Alkynyl heteroaromatic compound and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
- 1639US2022119517A1Anti-claudin18.2 antibody and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 1737US9963480B2Nucleoside phosphoramidate compound and use thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2014·Granted May 8, 2018·0 cites·18 claims
- 1835US10961222B2Chemical compound of isocitrate dehydrogenase inhibitor, and application thereofNANJING SANHOME PHARMACEUTICAL CO LTD·Filed 2017·Granted Mar 30, 2021·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when NANJING SANHOME PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →